These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35794643)

  • 1. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
    Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
    J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME immunohistochemistry of spitzoid neoplasms.
    Koh SS; Lau SK; Scapa JV; Cassarino DS
    J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
    Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
    Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
    Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
    Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
    McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
    J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
    Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
    Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.
    Kim YJ; Jung CJ; Na H; Lee WJ; Chang SE; Lee MW; Park CS; Lim Y; Won CH
    Diagn Pathol; 2022 Apr; 17(1):41. PubMed ID: 35484605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
    Wakefield C; O'Keefe L; Heffron CCBB
    Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
    Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
    Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRAME expression in melanocytic lesions of the nail.
    Parra O; Linos K; Li Z; Yan S
    J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
    Lohman ME; Steen AJ; Grekin RC; North JP
    J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ.
    Miao QJ; Zang J; Shao XB; Sun JF; Chen YP; Chen H
    J Clin Pathol; 2024 May; 77(6):417-420. PubMed ID: 36882315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
    Schmitt TA; Lee JC; Martinka M; Ko KYC
    J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
    Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
    Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi.
    Kim JC; Choi JW; Kim YC
    Am J Dermatopathol; 2023 Nov; 45(11):748-752. PubMed ID: 37856738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.